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ABSTRACT
Ciclosporin is widely used in a number of
inflammatory disorders and has the potential
for drug interactions. We report here a case of
acute kidney injury due to the interaction of
ciclosporin with methyl-1-testosterone. This
has not been previously reported and it is
relevant as methyl-1-testosterone can be
purchased online. Physicians should be aware
of any over the counter or online purchased
‘‘supplements’’ and consider possible drug
interactions.
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INTRODUCTION
Ciclosporin is widely used in a number of
inflammatory disorders and has the potential
for drug interactions [1]. We report here a case
of acute kidney injury due to the interaction of
ciclosporin with methyl-1-testosterone. This
has not been previously reported and it is
relevant as methyl-1-testosterone can be
purchased online.
CASE REPORT
A 29-year-old male patient with longstanding
atopic dermatitis was referred to the
dermatology outpatient department
(Dermatology Department, York Hospital, UK)
with a history of rapid deterioration of his
condition despite optimal topical therapy. Due
Electronic supplementary material The online
version of this article (doi:10.1007/s13555-013-0038-6)
contains supplementary material, which is available to
authorized users.
F. Al-Niaimi (&)




St. John’s Institute of Dermatology, St. Thomas’
Hospital, London, UK
C. C. Lyon
Dermatology Department, York Hospital, York, UK
Enhanced content for this article is
available on the journal web site:
www.dermtherapy-open.com
123
Dermatol Ther (Heidelb) (2013) 3:211–214
DOI 10.1007/s13555-013-0038-6
to the severity of the symptoms and condition,
he was started on systemic ciclosporin (3.0
mg/kg, twice daily). His ultimate ciclosporin
dose was 4.0 mg/kg which was gradually
increased from the initial dose of 3.0 mg/kg.
The patient’s baseline findings are presented in
Table 1. Good clinical response was achieved
whilst on ciclosporin and he was maintained on
it for 4 months (the later 3 months on the
maximum dose) with stable serial blood tests.
During routine follow-up, he was found to be
in acute renal impairment with urea of 17
lmol/L, creatinine of 266 lmol/L and
deranged liver function tests with bilirubin
37 lmol/L, alanine transaminase 304 U/L and
aspartate transaminase 48 IU/L. Investigations
included a urine dipstick and renal ultrasound
which were both normal. The ciclosporin level
during routine follow-up was elevated (trough
level 622 lmol/L) despite consistency with the
dose over 3 months and two stable previous
blood tests.
On direct questioning, the patient admitted
that he had been recently taking a
‘‘supplement’’. The patient had purchased this
over the Internet from an online shop and this
was dispatched along with some written
information. Subsequently, the ‘‘supplement’’
was found to be oral methyl-1-testosterone
(systematic name: 17 alpha methyl-17beta-
hydroxy-androst-1-ene-3-one). The patient
discontinued both ciclosporin and methyl-1-
testosterone and his renal function and liver
function tests returned to normal within
1 week. The patient had been administered
irregular amounts of methyl-1-testosterone
with no regular pattern. Atopic dermatitis
gradually flared up over 3 months and was
treated with ultraviolet B phototherapy as he
was reluctant to restart ciclosporin treatment.
Informed consent was obtained from the
patient for being included in the study. This
article does not contain any studies with
human subjects performed by any of the
authors.
DISCUSSION
A detailed review of pharmacokinetics and
metabolism of ciclosporin and sex steroids
revealed the likely cause of his acute kidney
injury. Ciclosporin is produced as a metabolite
by the fungus species Beauveria nivea and is
extensively metabolized by hepatic cytochrome
P-450 enzymes [1]. It is an immunosuppressive
agent with a narrow therapeutic index [2]. Since
ciclosporin is primarily metabolized by the
cytochrome P-450 enzymes in the liver and
hepatic function plays an important role in its
metabolism [1, 2], concurrent administration of
other drugs that are metabolized by the hepatic
P-450 enzyme system (e.g., ketoconazole) may
alter ciclosporin concentrations in the blood
[1, 2].
Methyl-1-testosterone is an orally active
derivative of the potent anabolic/androgenic
Table 1 The baseline ﬁndings for the patient
Test (units) Patient Normal
range
Blood pressure (mmHg) 125/70 –
Renal function test
Urea (lmol/L) 6.3 2.8–7.2
Creatinine (lmol/L) 93 59–104
Liver function test




Bilirubin (lmol/L) 12 1–25
IU international unit
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steroid 1-testosterone [3]. Methyl-1-testosterone
is an illegal, unlicensed drug and finds its way
into Internet commerce through lack of
regulations. Due to its structure, it is entirely
metabolized by the liver and has high
hepatotoxicity compared to other anabolic
steroids [4, 5].
Methyl-1-testosterone could compete with
ciclosporin for metabolization by microsomal
cytochrome P-450, the major recognized
metabolic pathway for both drugs in the liver
[6, 7]. Cholestasis is a well-recognized side effect
of methyl-1-testosterone and, as ciclosporin is
eliminated through biliary excretion, reduced
biliary flow can result in increased ciclosporin
levels leading to nephrotoxicity [3]. The peak
ciclosporin levels in our patient correlated with
the commencement of methyl-1-testosterone
administration and returned to normal within a
week of discontinuing it. Furthermore, the
blood tests were normal on two separate
occasions prior to the commencement of
methyl-1-testosterone administration despite
continuing on the same ciclosporin dose.
Testosterones are not listed in British
National Formulary as interacting with
ciclosporin [8]. In our patient, although it is
possible that the rise in creatinine could have
been due to an increase in the muscle bulk, the
trough ciclosporin level of 622 lmol/L is very
high, suggesting impaired metabolism. It is
recommended that in patients treated with
ciclosporin, renal and liver function tests
should be routinely monitored every 2 weeks
during the initial 3 months of therapy and then
monthly if the results are stable.
CONCLUSION
Prior to starting a patient on ciclosporin, a
careful drug history should include enquiries
about over-the-counter medications and
supplements purchased via the Internet. Our
case highlights the dangers of so-called
‘‘supplements’’ purchased online that can have
detrimental effects due to drug interactions. To
our knowledge, the interaction of methyl-1-
testosterone with ciclosporin has not been
reported in the literature.
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